Skip to main content

Iowa · Schedule I · A bill cleared one chamber

Iowa has the bill that traveled furthest — and it still isn't law.

Iowa is the surprise of this group. Psilocybin remains Schedule I, yet Iowa has moved a medical-psilocybin measure further than almost any conservative state. House File 978 — building on a 2025 version that cleared the Iowa House 84-6 — would create a state-regulated medical psilocybin program for PTSD and other conditions, with licensing run through a renamed Medical Cannabidiol Advisory Board. In March 2026 a Senate subcommittee advanced it. But a separate 2025 bill (HF 383), which would have let doctors prescribe synthetic psilocybin upon FDA approval, was vetoed by Gov. Kim Reynolds, who said it surrendered state authority to federal officials. So Iowa sits in an unusual place: a bill that has traveled remarkably far, stalled in the gap between House passage and law.

90-second quick read · research companion

Need the full research version?

This is the 90-second cliff-note read on imicrodosing.net. For the cited deep-dive companion, read the full .org research page before moving into product decisions.

Read the full .org research companion → Browse related 90-second reads →
Sch. ICurrent status
84-6House vote, 2025
HF 978Active bill 2026
Vetoed2025 companion

How far the bill has traveled

A measure stuck mid-journey

Most restrictive-state psilocybin bills die in committee. Iowa's cleared an entire chamber by a wide margin. The track below shows where it has reached — and where it stuck.

The bill's journey through the statehouse

Iowa medical psilocybin · 2025–2026

Origin

Filed

A veteran-backed program bill, modeled on Iowa's medical-cannabidiol framework.

House

Passed 84-6

The 2025 version cleared the Iowa House by a wide bipartisan margin.

Senate

In committee

HF 978 advanced from a Senate subcommittee in March 2026; not yet enacted.

Governor

Veto risk

A 2025 companion (HF 383) was vetoed over the federal-trigger mechanism.

Why this shape

Far along, but not the law

Iowa shows that broad legislative support is not the same as enactment. The House vote was lopsided, and the policy energy is real — driven by veterans and PTSD advocates. But a bill becomes law only after clearing both chambers and the governor, and Iowa's effort has been tripped at the later gates. Until a version is signed, psilocybin remains fully Schedule I in Iowa.

Four cities

Where Iowa's debate is centered

Iowa's psilocybin conversation runs through its largest metros and its university and medical hubs. Des Moines is the capital and statehouse. Cedar Rapids and Davenport anchor the eastern corridor. Iowa City is home to the University of Iowa and its academic medical center.

Common questions

Iowa psilocybin FAQ

Q · 01

Is psilocybin legal in Iowa?

No. Psilocybin is fully Schedule I in Iowa. A medical psilocybin bill has passed the Iowa House and is advancing in the Senate, but until a version is enacted, possession, cultivation, and sale remain criminal offenses.

Q · 02

What is Iowa House File 978?

HF 978 is a 2026 bill to create a state-regulated medical psilocybin program, primarily aimed at PTSD treatment. It would place oversight under a renamed Medical Cannabidiol Advisory Board. It advanced from a Senate subcommittee in March 2026 but has not become law.

Q · 03

Why was an earlier Iowa psilocybin bill vetoed?

In June 2025, Gov. Kim Reynolds vetoed HF 383, which would have let Iowa doctors prescribe a synthetic form of psilocybin if the FDA approved it. She objected that the bill surrendered state authority to make its own scheduling determination to federal officials.

Q · 04

Who is driving the Iowa psilocybin effort?

The push is led largely by veterans and PTSD advocates, with bipartisan legislative support. Supporters argue regulated, clinically supervised psilocybin could help Iowans, especially veterans, who have not responded to existing treatments.

While psilocybin stays Schedule I

iMicrodosing.com ships lab-verified products within all applicable federal, state, and local laws. For deeper research and clinical context on psilocybin therapy outcomes, imicrodosing.org aggregates the trial literature.